What is the core reason for the leadership change at PainChek (ASX:PCK)?

PainChek (ASX:PCK) appointed Karen Holzberger as chief executive officer following the board's announcement on July 6 regarding the departure of the previous CEO. The appointment becomes effective on Aug. 17.

How did the stock market react to the PainChek (ASX:PCK) announcement?

Following the leadership announcement, the PainChek (ASX:PCK) share price was unchanged at $0.105. The stock experienced no immediate price movement as a result of the transition news.

What are the upcoming headcount and executive changes at PainChek (ASX:PCK)?

Interim CEO Andy Hoggan will step down to return to his permanent role as chief operating officer on Aug. 17.

What is the commercial timeline for PainChek (ASX:PCK) in its new target segment?

PainChek (ASX:PCK) stated that initial deployments are already underway under a Master Services Agreement covering up to 20,000 beds. This rollout follows the company securing FDA De Novo clearance in 2025.

What geographic market impact does PainChek (ASX:PCK) expect from this appointment?

PainChek (ASX:PCK) forecasts that hiring a United States-based executive will drive its growth and commercialisation strategy in the North American market.

Image for illustrative purposes only. Not a real photo.

PainChek appoints Karen Holzberger as new CEO

Written by Mahathir BayenaPublished Jul 20, 2026, 1:01 AM

PainChek announced the appointment of United States-based medical technology leader Karen Holzberger as its new CEO, effective Aug. 17.
The company's stock experienced no immediate price movement following the leadership transition announcement.
The leadership change is intended to drive the company's growth strategy and commercialisation efforts in the United States market.

Medical device developer PainChek (ASX:PCK) has appointed Karen Holzberger as chief executive officer effective Aug. 17.

The appointment follows the board's announcement on July 6 regarding the departure of the previous chief executive.

“I am excited to join PainChek as CEO,” said PainChek's incoming CEO Karen Holzberger.

The company stated that the appointment supports its growth in the United States under an agreement covering up to 20,000 beds.

Following the announcement, the PainChek share price was unchanged at $0.105.

Holzberger possesses 26 years of industry experience and previously managed a diagnostic division at Nuance Healthcare.

Interim CEO Andy Hoggan will return to his role as chief operating officer on Aug. 17.

PainChek appoints Karen Holzberger as new CEO

Frequently asked questions

Assets related to this article